- Home
- IMMX
IMMX
Immix Biopharma Inc.
as 07-26-2024 4:00pm EST
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | LOS ANGELES |
| Market Cap: | 65.2M | IPO Year: | 2021 |
| Target Price: | $10.50 | AVG Volume (30 days): | 165.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.93 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.55 - $7.75 | Next Earning Date: | 08-09-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Immix Biopharma Inc. (IMMX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Rachman Ilya M | IMMX | CEO and Chairman | Jun 7 '24 | Buy | $2.13 | 2,600 | $5,538.00 | 1,136,259 | SEC Form 4 |
| Morris Gabriel S | IMMX | CFO | Jun 7 '24 | Buy | $2.12 | 2,500 | $5,298.00 | 285,834 | SEC Form 4 |
| Morris Gabriel S | IMMX | CFO | Jun 4 '24 | Buy | $1.81 | 3,300 | $5,972.67 | 283,334 | SEC Form 4 |
| Rachman Ilya M | IMMX | CEO and Chairman | Jun 4 '24 | Buy | $1.81 | 3,300 | $5,970.03 | 1,133,659 | SEC Form 4 |
| Morris Gabriel S | IMMX | CFO | May 14 '24 | Buy | $2.23 | 4,500 | $10,041.75 | 85,816 | SEC Form 4 |
| Rachman Ilya M | IMMX | CEO and Chairman | May 14 '24 | Buy | $2.25 | 4,300 | $9,659.95 | 912,000 | SEC Form 4 |
| Hsu Jason | IMMX | Director | Dec 8 '23 | Buy | $4.88 | 25,000 | $122,025.00 | 782,000 | SEC Form 4 |
| Hsu Jason | IMMX | Director | Dec 8 '23 | Buy | $4.67 | 31,000 | $144,894.00 | 813,000 | SEC Form 4 |
Latest Immix Biopharma Inc. News
IMMX Breaking Stock News: Dive into IMMX Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)
MT Newswires
18 days ago
Immix Biopharma Doses First Patient in US AL Amyloidosis Trial With NXC-201
GlobeNewswire
18 days ago
Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201
Simply Wall St.
24 days ago
Is Immix Biopharma (NASDAQ:IMMX) In A Good Position To Invest In Growth?
GlobeNewswire
a month ago
Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum
GlobeNewswire
2 months ago
RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships
Simply Wall St.
2 months ago
Immix Biopharma Insiders Placed Bullish Bets Worth US$625.7k
GlobeNewswire
3 months ago
Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation
Compare IMMX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMMX Immix Biopharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.